Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations by a Multivariant Surrogate Virus Neutralization Microarray
Preprint
- 15 November 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The capability of antibodies to neutralize different SARS-CoV-2 variants varies among individuals depending on the previous exposure to wild-type- or Omicron-specific immunogens by mono- or bivalent vaccinations or infections. Such profiles of neutralizing antibodies (nAbs) usually have to be assessed by laborious live virus-neutralization tests (NTs). We therefore analyzed whether a novel multivariant surrogate virus neutralization test (sVNT) (adapted from a commercial microarray) that quantifies the antibody-mediated inhibition between the receptor angiotensin-converting-enzyme 2 (ACE2) and variant-specific receptor-binding domains (RBDs) can assess the neutralizing activity against SARS-CoV-2 wild-type, Delta Omicron BA.1, BA.2 and BA.5 (sub-) variants after a booster with Omicron-adapted bivalent vaccines in a manner similar to live-virus NTs. Indeed, by using the live-virus NTs as a reference, we found a significant correlation between the variant-specific NT titers and levels of ACE2-RBD binding inhibition (p < 0.0001, r ≤ 0.78 respectively). Furthermore, the sVNTs identified higher inhibition values against BA.5 and BA.1 in individuals vaccinated with Omicron-adapted vaccines than in those with monovalent wild-type vaccines. Our data thus demonstrate the ability of sVNTs to detect variant-specific nAbs following a booster with bivalent vaccines.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variantsnpj Vaccines, 2023
- Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodiesThe Lancet Microbe, 2023
- Immunogenicity of BA.5 Bivalent mRNA Vaccine BoostersNew England Journal of Medicine, 2023
- BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variantsNature Communications, 2022
- Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based studyThe Lancet Regional Health - Europe, 2022
- Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccineCell Reports, 2022
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5New England Journal of Medicine, 2022
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infectionNature, 2022
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variantNature Medicine, 2022
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesCell, 2022